- Latest Entresto data have shown that initiating treatment with Novartis in a heart failure hospital has better results than the use of enalapril in the treatment.
- In the PIONEER-HF study, patients on Entresto recorded a key biomarker of severity and prognosis of nearly 30% compared to enalapril. Significant reductions in NT-proBNP levels of the hormone released after changes in heart rate have been reported within a week of commencing treatment with Entresto.
- After eight weeks of treatment, patients taking Novartis versus those taking enalapril experienced a 46% reduction in the composite re-hospitalization for heart failure; requiring the insertion of a left ventricular adjuster (LVAD); Heart transplant classification; and death.
Novartis clinical programs for Entresto (sacubitril and valsartan), including PIONEER and TRANSITION, have been building up some data over recent years. PIONEER-HF believes it now has the evidence needed to make Entresto the primary treatment for patients with heart failure with a reduced ejection fraction – a population with a high risk of death and re-hospitalization.
"Through Entresto's science program, we are re-prescribing the HFrEF Patient Care standard and using Entresto as the foundation therapy," said Shreeram Aradhye, chief medical officer at Novartis Pharmaceuticals, in a statement released November 11.
The results were presented at the American Heart Association during the weekend and published in the New England Journal of Medicine.
Novartis received the initial approval of Entresto in the US in July 2015 and in the EU a few months later. It would be a recommendation of Class 1 earnings in both geographical areas in 2016.
Drug receipts are growing rapidly, with the world's surge in the third quarter rising more than 100% year-on-year to $ 271 million.
He still has more data. The PARAGON trial is ongoing and evaluates patients with preserved ejection fraction and the results are expected in mid-2019. A PARADISE study evaluating Entresto in heart failure patients before heart failure is scheduled as scheduled.
"Overall, the image of Entresto looks strong, and we continue to see strong impulses around the world with this drug," Novartis Vas Narasimhan, CEO, said in the company's third quarter.